Status:
RECRUITING
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer
Lead Sponsor:
Leiden University Medical Center
Collaborating Sponsors:
Erasmus Medical Center
HollandPTC
Conditions:
Uterine Cervical Neoplasms
Locally Advanced Cervical Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This prospective, multicenter, nonrandomized phase-II-trial investigates in clinical practice the differences between intensity modulated proton therapy (IMPT) and standard intensity-modulated radiati...
Detailed Description
External beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy is a highly effective treatment for locally advanced cervical cancer (LACC). However, treatment-related to...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of cervical cancer (squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma, HPV positive or negative) with an indication for curative treatment with primary chemoradiation with concurrent cisplatin followed by 3D image-guided adaptive brachytherapy.
- Indication to include the common iliac region (minimum 5, maximum 8) or the common iliac and para-aortic regions (minimum 7, maximum 10) into the elective clinical target volume of the external beam radiotherapy.
- No distant metastasis beyond the para-aortic lymph node chain as determined by diagnostic imaging (CT or PET-CT scan)
- Age ≥ 18 years
- WHO 0-1
- Adequate systemic organ function:
- Creatinine clearance (\> 50 cc/min)
- Adequate bone marrow function : white blood cells (WBCs) ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l
- Patients must be accessible for treatment and follow-up
- Written informed consent according to the local Ethics Committee requirements
Exclusion
- Small cell cancer, melanoma and other rare histological types of the cervix.
- History of another primary malignancy that could conceivably be active evaluated by the study physician. Examples of exception include, but are not limited to:
- Malignancy treated with curative intent and with no known active disease ≥5 years.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- Other severe diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias
- Previous pelvic or abdominal radiotherapy
- History of active primary immunodeficiency
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g. colitis or Crohn's disease\])
- The use of immunosuppressive drugs at baseline
- Contraindications for weekly Cisplatin (or Carboplatin)
- Contraindications for the use of MRI
Key Trial Info
Start Date :
May 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05406856
Start Date
May 2 2022
End Date
December 1 2026
Last Update
October 11 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, Netherlands, 2333 ZA
2
Erasmus Medical Center
Rotterdam, Netherlands, 3015 GD